Anika Therapeutics (ANIK) Operating Leases (2019 - 2026)

Anika Therapeutics (ANIK) has 8 years of Operating Leases data on file, last reported at $23.8 million in Q1 2026.

• On a quarterly basis, Operating Leases rose 0.98% year-over-year to $23.8 million in Q1 2026; TTM through Mar 2026 was $23.8 million, a 0.98% increase from a year earlier, with the FY2025 full-year figure at $24.2 million, up 0.76% from the prior year.
• Operating Leases for Q1 2026 stood at $23.8 million, down from $24.2 million in the prior quarter.
• Over the last five years, Operating Leases for ANIK reached as high as $29.7 million in Q2 2022 and fell as low as $18.8 million in Q1 2022.
• Historically, Operating Leases has averaged $25.6 million across 5 years, with a median of $25.8 million in 2024.
• Across the five-year window, Operating Leases soared 50.27% in 2023 and fell 10.56% in 2025, its largest moves.
• Year by year, Operating Leases stood at $28.8 million in 2022, then fell by 10.07% to $25.9 million in 2023, then fell by 7.34% to $24.0 million in 2024, then climbed by 0.76% to $24.2 million in 2025, then decreased by 1.66% to $23.8 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $23.8 million in Q1 2026, $24.2 million in Q4 2025, and $22.8 million in Q3 2025.